When it comes to the body's healing process after significant injuries, such as fractures, burns, or major surgeries, the expectation is that tissues will mend and function will be restored. However, for some individuals, recovery can take a troubling and detrimental path. Instead of regenerating healthy muscle and tendon tissue, patients may experience the formation of new bone within soft tissues, which can lead to pain, stiffness, and long-lasting disabilities. This condition, known as heterotopic ossification (HO), frequently arises following trauma, joint replacement operations, or combat injuries, and often necessitates additional surgical interventions. Despite the profound effects on patients' lives, the underlying biological mechanisms have remained largely elusive.
A recent investigation led by Dr. Benjamin Levi and his team at the Center for Organogenesis, University of Texas Southwestern, has shed light on how two pivotal proteins, thrombospondin 1 (TSP1) and thrombospondin 2 (TSP2), contribute to abnormal bone growth following injuries by altering the composition of damaged tissues. This research not only clarifies how injured tissues become "reprogrammed" to foster bone generation but also opens up potential pathways for preventing this serious complication. The study's findings were published on January 19, 2026, in Volume 14 of the journal Bone Research.
Dr. Levi notes, "Our study demonstrates that these proteins are crucial in establishing the healing environment post-injury. When their activity is diminished, the occurrence of abnormal bone growth significantly decreases."
Previous studies have indicated that alterations in the extracellular matrix (ECM) might affect tissue repair; however, the specific molecular signals driving these changes were not well understood. The aim of this new research was to pinpoint the exact factors that influence the healing landscape following an injury.
To accomplish this, the researchers employed a well-established mouse model simulating burn and tendon injuries—traumas known to incite HO. The team meticulously tracked cellular and tissue transformations over time by utilizing advanced genetic techniques and imaging technologies. They integrated several methods, including single-cell RNA sequencing and spatial transcriptomics, alongside high-resolution imaging to scrutinize collagen fiber arrangements and three-dimensional scans to evaluate bone formation.
The results revealed that TSP1 was predominantly produced by immune cells called macrophages located at the injury's center, with lower levels found in mesenchymal progenitor cells (MPCs)—early-stage cells capable of becoming bone-forming cells. On the other hand, TSP2 was primarily generated by MPCs located around the periphery of the damaged area.
Moreover, the researchers discovered that these proteins influenced the organization of collagen fibers. During normal healing processes, collagen typically exhibits a flexible and loosely arranged structure. In contrast, when thrombospondin signaling is active in injured tissue, collagen fibers become tightly aligned, forming a configuration that supports new bone growth. To assess the necessity of these proteins, the team studied mice lacking both TSP1 and TSP2. They found that in these mice, collagen fibers were disorganized, leading to a marked reduction in abnormal bone growth.
Dr. Levi explains, "By eliminating both proteins, the tissue failed to create the necessary supportive framework for ectopic bone development, resulting in significantly less harmful bone formation."
Imaging scans confirmed that these mice exhibited much smaller bone deposits in tendons and adjacent tissues, while their normal skeletal structures remained unaffected. This finding implies that targeting these specific proteins could mitigate abnormal bone growth without disrupting healthy bone development.
Additionally, the study identified a regulatory protein named FUBP1 that modulates the production of TSP2. When levels of FUBP1 were reduced in laboratory-grown cells, there was a corresponding decrease in TSP2 levels, which weakened the signals that facilitate tissue remodeling. However, the authors caution that their conclusions are primarily based on animal models, and further research is necessary to determine if the same processes occur in humans and how safely these proteins can be targeted. Overall, this study provides valuable insights into the role of thrombospondin signaling in the development of HO after injuries.
Dr. Levi concludes, "HO can dramatically alter the lives of many individuals. By gaining a clearer understanding of the functions of TSP1 and TSP2 in the formation of HO, we aspire to develop therapies that specifically target these proteins to prevent HO before it inflicts irreversible damage."
This groundbreaking study invites readers to consider: how do you perceive the implications of these findings? Could targeting these proteins signal a new era in the treatment of HO, or do you think more extensive research is needed before we draw any conclusions? Share your thoughts!
